evaluation of sustained mrd negativity w/ daratumumab-combination regimens in relapsed refractory mm
Published 3 years ago • 164 plays • Length 40:47Download video MP4
Download video MP3
Similar videos
-
1:33:39
the relevance of mrd assessment in the clinical management of multiple myeloma (mm) patients
-
32:35
comy live 2020 - sessions 17
-
47:16
impact of a best practices program in patients with relapsed/refractory mm receiving selinexor
-
42:38
idh inhibitors in relapsed/refractory aml
-
2:34
mrd negativity rates following carfilzomib, dex & dara in r/r myeloma
-
4:03
maia and alcyone: follow-up of daratumumab in multiple myeloma
-
45:25
comy online 2020 - session 16
-
7:01
is mrd testing a standard of care?
-
0:55
sustained mrd negativity in multiple myeloma
-
1:44
risk assessment of multiple myeloma
-
34:36
highlights from asco / eha 2021: latest updates on myeloma
-
2:46
the forte trial: the value of sustained mrd negativity
-
1:27
maintenance therapy and mrd in myeloma
-
3:57
daratumumab in the treatment of mm with high-risk cytogenetics
-
4:20
what were the results of the determination trial presented at asco and eha?
-
42:12
hla-haploidentical vs matched unrelated donor trans. w posttrans. cyclophosphamide-based prophylaxis
-
3:10
the importance of mrd in multiple myeloma in guiding treatment decisions & access to therapies
-
2:57
when is the optimal time to measure minimal residual disease (mrd) in myeloma patients?